These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20303172)

  • 1. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib.
    Ikezoe T; Togitani K; Tasaka T; Nishioka C; Yokoyama A
    Leuk Res; 2010 Aug; 34(8):e200-1. PubMed ID: 20303172
    [No Abstract]   [Full Text] [Related]  

  • 2. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
    Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.
    Pieri L; Bosi A; Vannucchi AM
    Ann Hematol; 2010 Jul; 89(7):745-6. PubMed ID: 19953254
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
    Delomas T; Darné C; Besson C
    Leuk Lymphoma; 2012 Feb; 53(2):332-3. PubMed ID: 21823828
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
    Koury MJ; Newman JH; Murray JJ
    Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
    [No Abstract]   [Full Text] [Related]  

  • 6. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.
    Spataro V
    J Clin Oncol; 2011 Jan; 29(3):e50-2. PubMed ID: 20956624
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.
    Iurlo A; Fracchiolla NS; Ferla V; Cassin R; Gottardi E; Beghini A; Gianelli U; Spinelli O; Cortelezzi A
    J Clin Oncol; 2014 Apr; 32(10):e37-9. PubMed ID: 24449233
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
    Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
    Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.
    Cannella L; Breccia M; Loglisci G; Federico V; Santopietro M; Alimena G
    Acta Oncol; 2010 Apr; 49(3):399-400. PubMed ID: 20105089
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
    Cortes J; Ault P; Koller C; Thomas D; Ferrajoli A; Wierda W; Rios MB; Letvak L; Kaled ES; Kantarjian H
    Blood; 2003 Jun; 101(12):4714-6. PubMed ID: 12595304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
    Coutré S; Gotlib J
    Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
    Metzgeroth G; Erben P; Martin H; Mousset S; Teichmann M; Walz C; Klippstein T; Hochhaus A; Cross NC; Hofmann WK; Reiter A
    Leukemia; 2012 Jan; 26(1):162-4. PubMed ID: 21818111
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.
    Puissant A; Dufies M; Raynaud S; Cassuto JP; Auberger P
    Leukemia; 2010 May; 24(5):1099-101. PubMed ID: 20376083
    [No Abstract]   [Full Text] [Related]  

  • 16. [Spontaneous pneumothorax, an unusual manifestation of imatinib-resistant chronic eosinophilic leukemia: an autopsy study].
    Fujimi A; Kanisawa Y; Tanaka S; Okuda T; Sato Y; Doi T; Ohta H; Iwasaki S; Ishizu A; Huang Y
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):862-5. PubMed ID: 19432135
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
    Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha].
    Pottier P; Planchon B; Grossi O
    Rev Med Interne; 2003 Aug; 24(8):542-6. PubMed ID: 12888176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 20. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H; Nilsson O; Nilsson B
    Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.